Author Archives: UroGen
The Journal of Urology; January 2017; Volume 197, Issue 1, Pages 14–22 Donin NM1, Lenis AT1, Holden S1, Drakaki A1, Pantuck A1, Belldegrun A1, Chamie K2. 1 Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los … Continue reading
Ra’anana, Israel, April 24, 2017: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn “Kate” Falberg to its … Continue reading
AUA 2017, May 12-15. UroGen Pharma will exhibit at the American Urology Association Annual Meeting. We invite investigators interested in clinical collaboration to meet us in our Exposuite #366 or visit our booth #507 at the Exhibition Hall.
UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
RA’ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) — UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today that the first … Continue reading
Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility
Urol Oncol. 2017 Jan 3. Donin NM1, Strauss-Ayali D2, Agmon-Gerstein Y2, Malchi N2, Lenis AT3, Holden S3, Pantuck AJ4, Belldegrun AS4, Chamie K4. 1Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. 2UroGen Pharma Ltd., … Continue reading
UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma
-Plans to Initiate Single Pivotal, Open-Label, Single-Arm Phase 3 Clinical Trial in First Quarter of 2017- Ra’anana, Israel, New York, NY, December 12, 2016: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its … Continue reading
SUO poster presentation, Thursday, Dec 1, 2016 Andrew T. Lenis1, Karim Chamie1, Boris Friedman2, Andrea Tubaro3, Ami Sidi4, Daniel Kedar5, Lorenzo Colombo6, Dov Engelstein7, Joan Palau8, Gregory Wirth9, Ilan Leibovitch10, Eddy Fridman11, Ifat Klein12, Michal Jeshurun12, Fred Witjes13 1Department of Urology, … Continue reading
Thermo Reversible Hydrogel Base Delivery of Mitomycin C (MitoGel®) for Treatment of Upper Tract Urothelial Carcinoma (UTUC)
SUO poster presentation, Thursday, Dec 1, 2016 Jeffery Lin BS1, Nir Kleinmann MD2, Gregory Wirth MD3, Surena Matin MD4, Ofer Nativ MD5, Gil Mayer MD5, Fred Witjes MD6, Asaf Shvero MD2, Karim Chamie MD7, Allen Pantuck MD8, Angie Smith MD9, Mark … Continue reading
SUO 2016, Nov 30-Dec 2. UroGen Pharma will exhibit at the Society of Urology Oncology and meet investigators interested in clinical collaboration.
RAANANA, Israel, Oct. 14, 2016 — UroGen Pharma (“UroGen”), a privately-held, clinical-stage biotechnology company, announced today that it has completed an agreement to license worldwide rights to UroGen’s RTGelTM delivery system technology for use with neurotoxins to Allergan plc. RTGel™ … Continue reading